Market Intelligence, Clinical Progress, and High-Purity Reagents for Usher Syndrome and Hearing Loss Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for WHRN drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | WHRN Recombinant Protein (PDZ Domains / Full-Length) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View WHRN Products |
| Gene Delivery | WHRN Promise-ORF / Lentivirus Full-length ORF or custom truncations for stable cell lines. |
View WHRN Products |
| Benchmark Ab | Anti-WHRN Recombinant Antibody Sequence-verified positive control for Western Blot and IHC. |
View WHRN Products |
| Validator | WHRN siRNA Set For knockdown verification and specificity controls. |
View WHRN Products |
| Related Target A | USH2A (Usherin) Key interaction partner in the Usher syndrome hair bundle complex. |
View USH2A Products |
| Related Target B | ADGRV1 (GPR98) G-protein coupled receptor that co-localizes and binds with Whirlin. |
View ADGRV1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstituting PDZ domain interactions | Recombinant WHRN PDZ domain proteins strictly verified by mass spectrometry and sequence analysis. |
| Low transfection efficiency in sensory cells | Lentivirus Premade Particles optimized for stable transduction in sensory cell models. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies included |
| False Positives | Target-specific validated siRNA included for specificity checks |
Live WHRN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for WHRN therapeutics is intensifying, with major players shifting focus from traditional small molecules to gene therapy and genetic medicine. As first-generation therapies reach the clinic, the next wave of R&D is targeting precise macromolecular restoration of the Usher protein interactome in the inner ear and retina.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV) | Akouos (Eli Lilly), Decibel (Regeneron) | Usher Syndrome Type IID, DFNB31 | Expression validation (Need Lentivirus for stable lines) |
| ASO / RNA Editing | ProQR Therapeutics, Academic Spin-offs | Nonsense/Splice Mutations | In vitro knockdown/rescue (Need validated siRNA and ORF) |
| Small Molecule (PPI) | Preclinical Discovery Programs | Sensorineural Hearing Loss | Protein-Protein Interaction assays (Need Recombinant PDZ proteins) |